CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
PALO ALTO, Calif., October 21, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that five clinical and preclinical abstracts have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, which will be held in New Orleans, LA on November 8 - 12, 2008.
In addition, company chairman and chief executive officer Louis G. Lange, M.D., PhD. will present at an AHA plenary session on November 12, 2008, 9:00 a.m. CST.
The accepted abstracts relate to several different topics, as follows:
Poster Presentation, Monday, November 10, 2008, 3:00 p.m. CST
Poster Presentation, Sunday, November 9, 2008, 9:30 a.m. CST
Oral Presentation, Wednesday, November 12, 2008, 4:15 p.m. CST
Oral Presentation, Tuesday, November 11, 2008, 9:00 a.m. CST
; Poster Presentation, Wednesday, November 12, 2008, 9:00 a.m. CST
Additional information regarding the AHA Scientific Sessions 2008 can be accessed at http://scientificsessions.org.
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.
CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.
Posted: October 2008